Key Takeaways The AMPLIFY trial evaluates 64Cu-SAR-bisPSMA's efficacy in detecting prostate cancer lesions in patients with biochemical recurrence. 64Cu-SAR-bisPSMA has received FDA fast track ...

Patel also touched on the implications of these findings for clinical practice. “The implications of this are pretty significant. I think we do need to be aware of the fact that, whether it be due to ...

Key Takeaways Promontory Therapeutics will initiate a phase 3 trial of PT-112 for mCRPC following a positive FDA meeting. PT-112 induces immunogenic cancer cell death and targets bone disease sites, ...

On April 28, 2025, in Las Vegas, Nevada, Urology Times ® hosted a Clinical Forum program on the topic of bladder-preserving innovations and next-generation therapies for non–muscle invasive bladder ...

The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

In 2025, cytoreductive nephrectomy (CN) remains an integral part of the multidisciplinary management of metastatic renal cell carcinoma (mRCC). Rapid advances in systemic therapies—particularly immune ...

Treatment Options for mHSPC Key Themes: Current 2025 guidelines recommend ADT with intensification. Multiple intensification options include abiraterone, darolutamide, and docetaxel. Key clinical ...

Strengths and Limitations of Different Imaging Modalities Main Discussion Topics: CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing ...

A groundbreaking milestone was reached earlier this month as urologic surgeons from the University of Southern California (USC) and the University of California, Los Angeles (UCLA) collaborated to ...

During the interview, Razavi was asked, given the significant increase in overall fatigue post-ureteroscopy, particularly among female surgeons, to elaborate on potential ergonomic or procedural ...

Multifactorial Causes of Racial Disparities Clinical Trial Representation Key Themes: Black men are significantly underrepresented in prostate cancer clinical trials (<5% in most studies). Many trials ...

Former President Joe Biden has been diagnosed with grade group 5 de novo metastatic hormone-sensitive prostate cancer, according to a recent announcement from his office. 1 This diagnosis has raised ...